Published June 24, 2026 · Auto-generated from the S-1/A filing — every claim sourced.

Neutron Holdings, Inc. (LIME): what the S-1/A says

Neutron Holdings, Inc. has a S-1/A filing dated 2026-06-22 for its NASDAQ listing (US). Expected: Jul 1, 2026 · Price range: $24 – $26 · Offer size: $180,869,572.

Use of proceeds (from the filing)

• estimate that we will receive net proceeds from this offering of approximately $141.6 million (or $165.8 million if the underwriters exercise their option to purchase additional shares of common stock from us in full), based on an assumed initial public offering price of $25.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting e
• We will not receive any proceeds from the sale of common stock by the selling stockholders
• The principal purposes of this offering are to obtain additional capital to fund our operations, create a public

Filing-grounded SWOT (excerpt)

Strengths

• The offering comprises 6,956,522 shares priced between $24.00 and $26.00, creating a gross proceeds potential of approximately $180,869,572.
• Listing on NASDAQ will give Neutron Holdings, Inc. immediate access to a deep and liquid public market, enhancing visibility and credibility.
• The underwriters' over‑allotment option could increase net proceeds to $165.8 million if fully exercised, providing additional financial flexibility.

Risks / weaknesses

• The company will not receive any proceeds from the sale of common stock by the selling stockholders, limiting total capital to the net proceeds from the offering alone.
• Net proceeds of $141.6 million are calculated after deducting underwriting discounts, commissions, and offering expenses, reducing the cash available for operations.
• Neutron Holdings, Inc. is relying on a single capital raise to fund its operations, exposing it to execution risk if the offering does not close as expected.

Source: S-1/A on SEC EDGAR · Full research: LIME IPO page (Sharia sector screen, timeline, FAQ).

Research and analysis only — not investment advice, not a recommendation to apply or avoid.